475 related articles for article (PubMed ID: 38258110)
1. Targeted Glioma Therapy-Clinical Trials and Future Directions.
Shikalov A; Koman I; Kogan NM
Pharmaceutics; 2024 Jan; 16(1):. PubMed ID: 38258110
[TBL] [Abstract][Full Text] [Related]
2. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
3. Advances in Glioblastoma Therapy: An Update on Current Approaches.
Angom RS; Nakka NMR; Bhattacharya S
Brain Sci; 2023 Oct; 13(11):. PubMed ID: 38002496
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
5. Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme.
Tilak M; Holborn J; New LA; Lalonde J; Jones N
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33673213
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery.
Brar HK; Jose J; Wu Z; Sharma M
Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678688
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic strategies of recurrent glioblastoma and its molecular pathways 'Lock up the beast'.
El-Khayat SM; Arafat WO
Ecancermedicalscience; 2021; 15():1176. PubMed ID: 33680090
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
[TBL] [Abstract][Full Text] [Related]
9. Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions.
Patel M; Vogelbaum MA; Barnett GH; Jalali R; Ahluwalia MS
Expert Opin Investig Drugs; 2012 Sep; 21(9):1247-66. PubMed ID: 22731981
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
Zhao HF; Wang J; Shao W; Wu CP; Chen ZP; To ST; Li WP
Mol Cancer; 2017 Jun; 16(1):100. PubMed ID: 28592260
[TBL] [Abstract][Full Text] [Related]
11. Glioblastoma multiforme: State of the art and future therapeutics.
Wilson TA; Karajannis MA; Harter DH
Surg Neurol Int; 2014; 5():64. PubMed ID: 24991467
[TBL] [Abstract][Full Text] [Related]
12. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment.
Verdugo E; Puerto I; Medina MÁ
Cancer Commun (Lond); 2022 Nov; 42(11):1083-1111. PubMed ID: 36129048
[TBL] [Abstract][Full Text] [Related]
13. Systematic Review of Molecular Targeted Therapies for Adult-Type Diffuse Glioma: An Analysis of Clinical and Laboratory Studies.
Muzyka L; Goff NK; Choudhary N; Koltz MT
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445633
[TBL] [Abstract][Full Text] [Related]
14. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
15. Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress.
Wang Y; Chen W; Shi Y; Yan C; Kong Z; Wang Y; Wang Y; Ma W
Front Oncol; 2021; 11():719623. PubMed ID: 34568049
[TBL] [Abstract][Full Text] [Related]
16. Emerging drugs for malignant glioma.
Mason WP
Expert Opin Emerg Drugs; 2008 Mar; 13(1):81-94. PubMed ID: 18321150
[TBL] [Abstract][Full Text] [Related]
17. Nanotechnology meets glioblastoma multiforme: Emerging therapeutic strategies.
Liu D; Dai X; Ye L; Wang H; Qian H; Cheng H; Wang X
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023 Jan; 15(1):e1838. PubMed ID: 35959642
[TBL] [Abstract][Full Text] [Related]
18. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
19. Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells.
Reddy RG; Bhat UA; Chakravarty S; Kumar A
Cancer Chemother Pharmacol; 2020 Aug; 86(2):165-179. PubMed ID: 32638092
[TBL] [Abstract][Full Text] [Related]
20. NcRNAs: Multi‑angle participation in the regulation of glioma chemotherapy resistance (Review).
Zeng Z; Chen Y; Geng X; Zhang Y; Wen X; Yan Q; Wang T; Ling C; Xu Y; Duan J; Zheng K; Sun Z
Int J Oncol; 2022 Jun; 60(6):. PubMed ID: 35506469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
